소아청소년에서 Coronavirus Disease 2019 백신에 대한 이상 반응
Adverse reactions to coronavirus disease 2019 vaccines in children and adolescents
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The incidence of coronavirus diseases 2019 (COVID-19), including severe cases, has been increasing in both children and adolescents with the spread of the delta variant. COVID-19 vaccines have been identified to be effective in the prevention of COVID-19 transmission in children and adolescents and keeping schools open. However, adverse reactions associated with COVID-19 vaccination in children and adolescents contribute to parents’ hesitation to proceed with vaccination, especially due to serious, albeit rare, reactions. The results from COVID-19 vaccine clinical trials on the safety and efficacy of COVID-19 vaccines in children and adolescents are promising in terms of their effects on COVID-19 infection prevention. In the present study, we summarize the adverse reactions of COVID-19 vaccines in children and adolescents, based on the clinical trials, mainly including Pfizer-BioNTech and Moderna COVID-19 vaccines. In the Pfizer-BioNTech COVID-19 clinical trials, the most common local adverse reaction was pain at the injection site in 74.1%–86%, depending on age, and the most common systemic adverse reaction was fatigue, followed by headache, myalgia, diarrhea, and fever with differences in the distribution according to age. There was no severe adverse reaction related to any COVID-19 vaccine in children and adolescents during the study period. In the mass vaccination program of COVID-19 in children and adolescent, myocarditis has rarely been diagnosed after COVID-19 vaccination, which most commonly occurred in boys after the second dose. Currently, Pfizer-BioNTech COVID-19 vaccines can be safely recommended in children and adolescents for the prevention of COVID-19 infection and the reduction in COVID-19 severity.
Abstract
The incidence of coronavirus diseases 2019 (COVID-19), including severe cases, has been increasing in both children and adolescents with the spread of the delta variant. COVID-19 vaccines have been identified to be effective in the prevention of COVID-19 transmission in children and adolescents and keeping schools open. However, adverse reactions associated with COVID-19 vaccination in children and adolescents contribute to parents’ hesitation to proceed with vaccination, especially due to serious, albeit rare, reactions. The results from COVID-19 vaccine clinical trials on the safety and efficacy of COVID-19 vaccines in children and adolescents are promising in terms of their effects on COVID-19 infection prevention. In the present study, we summarize the adverse reactions of COVID-19 vaccines in children and adolescents, based on the clinical trials, mainly including Pfizer-BioNTech and Moderna COVID-19 vaccines. In the Pfizer-BioNTech COVID-19 clinical trials, the most common local adverse reaction was pain at the injection site in 74.1%–86%, depending on age, and the most common systemic adverse reaction was fatigue, followed by headache, myalgia, diarrhea, and fever with differences in the distribution according to age. There was no severe adverse reaction related to any COVID-19 vaccine in children and adolescents during the study period. In the mass vaccination program of COVID-19 in children and adolescent, myocarditis has rarely been diagnosed after COVID-19 vaccination, which most commonly occurred in boys after the second dose. Currently, Pfizer-BioNTech COVID-19 vaccines can be safely recommended in children and adolescents for the prevention of COVID-19 infection and the reduction in COVID-19 severity.
참고문헌 (24)
- Galindo R, "COVID-19 in children : clinical manifestations and pharmacologic interventions including vaccine trials", Pediatr Clin North Am, 68, pp.961~976 (2021)
- Murthy BP, "COVID-19 vaccination coverage among adolescents aged 12-17 years-United States, December 14, 2020-July 31, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1206~1213 (2021)
- Siegel DA, "Trends in COVID-19 cases, Emergency Department visits, and hospital admissions among children and adolescents aged 0-17 years-United States, August 2020-August 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1249~1254 (2021)
- "Coronavirus (COVID-19), Republic of Korea. Current status of occurrence in Korea" (2021)[URL]
- Loenenbach A, "SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021", Euro Surveill, 26, pp.2100433~ (2021)
- "REACT-1 round 13 interim report : acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021" (2021)[URL]
- "Children and COVID-19: state-level data report" (2022)[URL]
- Havers FP, "Hospitalization of adolescents aged 12-17 years with laboratory-confirmed COVID-19-COVID-NET, 14 States, March 1, 2020-April 24, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.851~857 (2021)
- Gurdasani D, "Vaccinating adolescents against SARS-CoV-2 in England : a risk-benefit analysis", J R Soc Med, 2021 (2021)
- Moghadas SM, "Simulated identification of silent COVID-19 infections among children and estimated future infection rates with vaccination", JAMA Netw Open, 4, pp.e217097~ (2021)
- "U.S. Food and Drug Administration" (2021)[URL]
- Moss WJ, "Pediatric COVID-19 vaccines : what parents, practitioners, and policy makers need to know", JAMA, 326, pp.2257~2258 (2021)
- "Current status of COVID-19 outbreak and vaccination in Korea" (2021)[URL]
- Perez Y, "Myocarditis following COVID-19 mRNA vaccine : a case series and incidence rate determination", Clin Infect Dis (2021)[DOI]
- Frenck RW Jr, "Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents", N Engl J Med, 385, pp.239~250 (2021)
- "Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document US Food and Drug Administration" (2021)[URL]
- Ali K, "Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents", N Engl J Med, 385, pp.2241~2251 (2021)
- Engler RJ, "A prospective study of the incidence of myocarditis", pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination, 2015, pp.10, e0118283~
- Dionne A, "Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children", JAMA Cardiol, 6, pp.1446~1450 (2021)
- Alhumaid S, "Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines : a systematic review and meta-analysis", Allergy Asthma Clin Immunol, 17, pp.109~ (2021)
- Warren CM, "Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US Regional Health System", JAMA Netw Open, 4, pp.e2125524~ (2021)
- Nilsson L, "Vaccine allergy : evidence to consider for COVID-19 vaccines", Curr Opin Allergy Clin Immunol, 21, pp.401~409 (2021)
- Sellaturay P, "Polyethylene glycol(PEG)is a cause of anaphylaxis to the Pfizer", BioNTech mRNA COVID-19 vaccine, 2021, pp.51, 861~863
- Rutkowski K, "Adverse reactions to COVID-19 vaccines : a practical approach", Clin Exp Allergy, 51, pp.770~777 (2021)